Skip to main content
Frontiers in Public Health logoLink to Frontiers in Public Health
. 2024 Jun 14;12:1377135. doi: 10.3389/fpubh.2024.1377135

A retrospective analysis of the influencing factors of nucleic acid CT value fluctuation in COVID-19 patients infected with Omicron variant virus in Changchun city

Zhenghua Cao 1, Feng Sun 2, Huan Ding 2, Zhiyu Tian 1, Yingzi Cui 2, Wei Yang 2, Shaodan Hu 2,*, Li Shi 2,*
PMCID: PMC11211536  PMID: 38947348

Abstract

Objective

This study aimed to determine the risk factors associated with fluctuations in nucleic acid CT values in patients infected with the Omicron variant during an outbreak at a hospital in Changchun city.

Methods

A retrospective analysis was conducted on general information, medical history, vaccination history, and laboratory test data of COVID-19 patients infected with the Omicron variant and admitted to the hospital in Changchun from March 2022 to April 2022. The study aimed to explore the factors influencing nucleic acid CT value fluctuations in COVID-19 patients infected with the Omicron variant in Changchun city.

Results

Fluctuations in nucleic acid CT values were significantly correlated with occupation composition (p = 0.030), hospital stay duration (p = 0.000), heart rate (p = 0.026), creatinine (p = 0.011), platelet count (p = 0.000), glutamic-pyruvic transaminase (p = 0.045), and glutamic oxaloacetic transaminase (p = 0.017). Binary logistic regression analysis revealed significant correlations between hospital stay duration (p = 0.000), platelet count (p = 0.019), heart rate (p = 0.036), and nucleic acid CT value fluctuations (p < 0.05), indicating that they were independent risk factors. Red blood cell count was identified as a factor influencing nucleic acid CT value fluctuations in Group A patients. Occupation composition, direct bilirubin, and platelet count were identified as factors influencing nucleic acid CT value fluctuations in Group B patients. Further binary logistic regression analysis indicated that occupational composition and direct bilirubin are significant independent factors for nucleic acid CT value fluctuations in Group B patients, positively correlated with occupational risk and negatively correlated with direct bilirubin.

Conclusion

Therefore, enhancing patients’ immunity, increasing physical exercise to improve myocardial oxygen consumption, reducing the length of hospital stays, and closely monitoring liver function at the onset of hospitalization to prevent liver function abnormalities are effective measures to control fluctuations in nucleic acid CT values.

Keywords: COVID-19, Omicron variant, fluctuation of nucleic acid CT values, retrospective analysis, risk factors

1. Introduction

In December 2019, the emergence of the novel coronavirus pneumonia (COVID-19, 2019-nCoV, or SARS-CoV-2) continued to perplex the entirety of human society. It has impacted not only the healthcare systems but also the equilibrium of the global socio-economic landscape (1, 2). The Omicron variant, known for its high transmissibility and immune evasion capabilities (3), can rapidly become the dominant strain in a region. However, it primarily infects the upper respiratory tract rather than the lower respiratory tractt (4), resulting in decreased pathogenicity and slower spread from the main bronchi to the distal bronchioles, leading to significant improvements in pulmonary histopathology and lung disease (5–7). The majority of patients may experience mild symptoms or remain asymptomatic (8, 9). Studies have indicated that Omicron possesses enhanced contagiousness and the ability to evade vaccine protection (10, 11). Real-time reverse transcription polymerase chain reaction (RT-PCR) can be employed for screening and diagnosing Omicron infections, closely associated with viral culture (12, 13). The virus may still be detected in individuals even 0–2 days after symptom resolution (14). Thus, monitoring the fluctuation of the patient’s nucleic acid cycle threshold (CT) values is crucial.

Over the past 3 years, there have been recurrent small-scale outbreaks of the pandemic, which have significantly affected the physical and mental health of the population. Research has revealed that a majority of individuals have developed a fear of the Omicron variant (15), with a temporary increase in emotional and anxiety disorders (16), leading to long-lasting psychological sequelae, albeit unevenly distributed (17). However, under the anti-pandemic measures implemented in China, it has been observed that the Chinese population’s fear of the Omicron variant has gradually diminished, while positive emotions have increased (18). As the number of infected individuals continues to rise, our clinical observations have indicated that fluctuations in the nucleic acid CT values of hospitalized COVID-19 patients can have an impact on their mood, potentially prolonging their recovery time and impacting their health. A plethora of systematic reviews and observational studies have established that nucleic acid CT values are not only correlated with the progression to severe illness, disease severity, and clinical biomarkers (19–21), but also bear significant associations with demographic factors and clinical histories (22–24). It has been observed that males exhibit higher viral loads compared to females (25), which can predict their infectiousness (26) and potentially reduce the likelihood of transmission (27). Consequently, CT values can serve as prognostic markers at an individual level (28, 29), identifying patients with higher morbidity and risk (30). Therefore, it is crucial to consider nucleic acid CT values in the management of COVID-19 infections (31), and to emphasize the importance of early testing (32). Further research indicates that fluctuations in CT values are linked with respiratory symptoms, comorbidities, and abnormalities in chest imaging (33), and may exacerbate the incidence of depression and insomnia (34). Prompt attention to the dynamic changes in CT values (35) will aid in monitoring the infection status of patients (36).

Therefore, this study aims to retrospectively analyze general information, medical history, vaccination records, laboratory tests, and other data of COVID-19 patients infected with the Omicron variant in Changchun, Jilin Province, China, in March 2022. Through statistical analysis of the collected data, we aim to explore the factors associated with fluctuations in patients’ nucleic acid CT values.

2. Materials and methods

2.1. General data of patients

The diagnostic criteria and fluctuation of nucleic acid CT values are referenced from the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 9) issued by the National Health Commission and the National Administration of Traditional Chinese Medicine (37). All COVID-19 patients undergo nucleic acid testing conducted by professionals at the same time and location, using specialized nucleic acid sampling techniques. The tests are uniformly processed using machines and reagent kits from the same batch and manufacturer. The Fluorescent Quantitative PCR method is employed, and results are interpreted strictly according to the kit’s specifications. The process includes initial screening, retesting, and CDC review to minimize potential errors. All test results adhere to the guidelines set forth in the “Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 9)” issued by the National Health Commission and the National Administration of Traditional Chinese Medicine. The term “nucleic acid CT value fluctuation” refers to the scenario where a patient’s initial post-admission nucleic acid test is negative, marked as Day 1 with a CT value greater than 35, and the Day 2 test also shows a CT value greater than 35, but on Day 3, the CT value drops below 35, leading to a delayed discharge termed as nucleic acid CT value fluctuation.

2.2. Laboratory index and TCM diagnosis

Collection of general information, medical history, vaccination history, and laboratory examination data of COVID-19 patients who were hospitalized and infected with the Omicron variant at the Affiliated Hospital of Changchun University of Traditional Chinese Medicine from March 2022 to April 2022. Based on the results of the patients’ nucleic acid tests, they were divided into two groups: the nucleic acid CT value fluctuation group and the nucleic acid CT value non-fluctuation group. Patients were further divided based on the length of hospital stay: those hospitalized for more than 10 days were placed in Group A, while those hospitalized for 10 days or less were placed in Group B.

2.3. Statistical analysis

A database was constructed using WPS 2023 spreadsheet, and SPSS 20.0 was used for statistical analysis. Descriptive statistics such as frequency and percentage were used for categorical data, and the chi-square test was used for between-group comparisons. For normally distributed continuous data, mean and standard deviation were used for description, while non-normally distributed continuous data were described using median [P25, P75]. Logistic regression analysis was utilized to identify risk factors of nucleic acid CT value fluctuation. A significance level of p < 0.05 was considered statistically significant.

2.4. Ethical review

This study has been approved by the Ethics Committee of the Affiliated Hospital of Changchun University of Traditional Chinese Medicine (Approval No: CCZYFYLL2022 Approval Letter-020; CCZYFYLL2022 Approval Letter-021). All patients provided written or verbal informed consent prior to participation.

3. Results

3.1. General information of patients

This research collected data from 927 COVID-19 patients, categorizing them based on their nucleic acid test results into two groups: a stable CT value group with 660 cases and a fluctuating CT value group with 267 cases. Among the group with stable nucleic acid CT values, there were 388 males and 272 females, with a mean age of 40.27 ± 16.102 years. In the group with fluctuating nucleic acid CT values, there were 162 males and 105 females, with a median age of 41 [31, 53] years. There were no statistically significant differences between the two groups in terms of age, gender composition, vaccination history, medical history, and pre-admission treatment (p > 0.05). However, there was a statistically significant difference in the occupational composition between the two groups (χ2 = 7.043, p = 0.03) (Table 1).

Table 1.

Comparison of basic information of patients [Example (%)].

Clinical data Total (927) Category χ2/z p
Stable nucleic acid CT values (660) Fluctuating nucleic acid CT values (267)
Age 40.27 ± 16.102 41 [31,53] −1.031 0.302
Sex 0.28 0.596
Male 550 (59.33) 388 (58.79) 162 (60.67)
Female 377 (40.67) 272 (41.21) 105 (39.33)
Occupation 7.043 0.03*
Low-risk occupation 88 (9.49) 52 (7.88) 36 (13.48)
Medium risk occupation 454 (48.98) 327 (49.54) 127 (47.57)
High-risk occupation 385 (41.53) 281 (42.58) 104 (38.95)
Vaccine 0.000 0.988
Unvaccinated 59 (6.39) 42 (6.39) 17 (6.37)
Vaccinated 865 (93.61) 615 (93.61) 250 (93.63)
Previous history 3.261 0.071
Yes 130 (14.1) 84 (12.79) 46 (17.36)
No 792 (85.9) 573 (87.21) 219 (82.64)
Treatment before admission 0.178 0.673
No 827 (89.21) 587 (88.94) 240 (89.89)
Yes 100 (10.79) 73 (11.06) 27 (10.11)

*p < 0.05, the difference is statistically significant.

3.2. Laboratory indicators and traditional Chinese medicine (TCM) syndrome differentiation

There were statistically significant differences between the group with stable nucleic acid CT values and the group with fluctuating nucleic acid CT values in terms of hospital stay duration (z = −12.672, p = 0.000), heart rate (z = −2.224, p = 0.026), creatinine (z = −2.545, p = 0.011), platelet count (z = −3.502, p = 0.000), glutamic-pyruvic transaminase (z = −2.006, p = 0.045), and glutamic oxaloacetic transaminase (z = −2.388, p = 0.017). However, there were no statistically significant differences between the two groups in terms of TCM symptoms at admission, fever after admission, comprehensive evaluation of medical records, TCM diagnosis at discharge, and various indicators (temperature, breath, systolic blood pressure, diastolic blood pressure, oxygen saturation, total bilirubin, direct bilirubin, red blood cell count, white blood cell count, bacterial count, hemoglobin, albumin, blood urea nitrogen, NLR) (p > 0.05) (Tables 2, 3).

Table 2.

Comparison of clinical data of patients after admission [P25, P75].

Clinical data Total (927) Category χ2/z p
Stable nucleic acid CT values (660) Fluctuating nucleic acid CT values (267)
Hospital stay duration 10 [8,11] 12 [10,14] −12.672 0.000*
TCM symptom 0.584 0.445
No 133 (14.35) 91 (13.79) 42 (15.73)
Yes 794 (85.65) 569 (86.21) 225 (84.27)
Fever after admission 2.810 0.094
Yes 192 (58.54) 129 (55.60) 63 (65.63)
No 136 (41.46) 103 (44.40) 33 (34.38)
Comprehensive evaluation of admission records 2.931 0.231
Light 790 (98.26) 570 (98.62) 220 (97.35)
Ordinary 14 (1.74) 8 (1.38) 6 (2.65)
Discharged TCM diagnosis 0.819 0.664
Lung meridian stagnation fire syndrome 520 (56.10) 365 (55.30) 155 (58.05)
Evidence of cold and dampness invading outside 375 (40.45) 273 (41.36) 102 (38.20)
Others 32 (3.45) 22 (3.33) 10 (3.75)

*p < 0.05, the difference is statistically significant.

Table 3.

Comparison of all indicators in patients [P25, P75].

Various indicators Category z p
Stable nucleic acid CT values (660) Fluctuating nucleic acid CT values (267)
Temperature 36.5 [36.2, 36.7] 36.5 [36.2, 36.7] −0.221 0.825
Breath 18 [18, 20] 18 [18, 20] −0.596 0.551
Heart rate 90 [80, 100] 88 [80, 100] −2.224 0.026*
Systolic blood pressure 120 [120, 130] 120 [120, 129] −0.283 0.777
Diastolic blood pressure 80 [74, 83] 80 [70, 82] −0.673 0.501
Blood oxygen saturation 98 [96, 99] 98 [97, 99] −0.003 0.998
Total bilirubin 10.3 [6.725, 13.975] 10.5 [7.5, 13.9] −0.880 0.379
Direct bilirubin 2.9 [1.225, 4.0] 3.1 [1.8, 4.2] −1.523 0.128
Creatinine 60.5 [41, 76] 66 [50, 78] −2.545 0.011*
Red blood cell count 4.85 [1.8, 13.8] 4.8 [1.5, 12.4] −0.630 0.529
White blood cell count 8.2 [3.6, 21.975] 7.0 [3.8, 16.8] −1.122 0.262
Bacterial count 21.9 [4.6, 151.475] 13.4 [4.4, 141.2] −0.928 0.353
Hemoglobin 144 [131, 158] 144 [130, 157] −0.734 0.463
Platelet count 205 [169, 250] 189 [159, 235] −3.502 0.000*
Albumin 42.05 [38.125, 44.175] 42.2 [39.3, 44.6] −1.129 0.259
Glutamic-pyruvic transaminase 18 [9, 32] 21 (12, 34) −2.006 0.045*
Glutamic oxaloacetic transaminase 20 [14, 26] 21 [16, 28] −2.388 0.017*
Urea nitrogen 3.9 [2.7, 4.9] 4.0 [3.1, 4.9] −1.143 0.253
NLR (Neutral Particle Count/Lymphocyte Count) 1.36 [0.94, 1.9775] 1.33 [0.85, 1.96] −0.936 0.349

*p < 0.05, the difference is statistically significant.

3.3. Logistic regression analysis of factors influencing nucleic acid CT value fluctuations

Factors that showed statistically significant differences in the univariate analysis, including hospital stay duration, heart rate, creatinine, platelet count, glutamic-pyruvic transaminase and glutamic oxaloacetic transaminase, were included in a binary logistic regression model. Nucleic acid CT value fluctuation was the dependent variable, and the six aforementioned variables, along with age as a forced variable, were entered into the model using a forward: LR method. The results showed that hospital stay duration (p = 0.000, OR = 1.399), heart rate (p = 0.036, OR = 0.979), and platelet count (p = 0.019, OR = 0.996) were significantly associated with nucleic acid CT value fluctuations. None of the other indicators were independent risk factors for nucleic acid CT value fluctuations (p > 0.05) (Table 4).

Table 4.

Logistic regression analysis of the fluctuation factors of nucleic acid CT value of patients.

Risk factors OR (95%CI) p
Hospital stay duration 1.399 (1.259–1.546) 0.000*
Age 0.213 (0.966–1.007) 0.164
Heart rate 0.979 (0.960–0.999) 0.036*
Platelet count 0.996 (0.993–0.999) 0.019*

*p < 0.05, the difference is statistically significant.

3.4. Comparison of baseline data between two groups

Since nucleic acid CT value fluctuations were positively correlated with hospital stay duration, the patients were further divided into Group A and Group B based on a median hospital stay duration of 10 days. In group A, there were 233 cases in the non-fluctuation group of nucleic acid CT value, including 139 males and 94 females, with a median age of 39 (30, 38) years, and 185 cases in the fluctuation group of nucleic acid CT value, including 115 males and 70 females, with a median age of 43 (31, 38) years. In group B, there were 427 cases in the non-fluctuation group of nucleic acid CT value, including 249 males and 178 females, with a median age of 39 (28, 38) years, and 82 cases in the fluctuation group of nucleic acid CT value, including 47 males and 35 females, with a median age of 34 (28, 39) years. There were no statistically significant differences between the two groups in terms of age, gender composition, vaccination history, medical history, and treatment before admission (p > 0.05). However, there was a statistically significant difference in the occupational composition between the two groups (χ2 = 6.012, p = 0.049) (Table 5).

Table 5.

Comparison of basic information of patients with different length of stay [Example (%)].

Hospital stay duration Clinical data Total Category χ2/z p
Stable nucleic acid CT values (660) Fluctuating nucleic acid CT values (267)
Group A 418 233 185
Age 39 [30, 52] 43 [31, 52] −1.262 0.207
Sex 0.272 0.602
Male 254 (60.77) 139 (59.66) 115 (62.16)
Female 164 (39.23) 94 (40.34) 70 (37.84)
Occupation 0.641 0.726
Low-risk occupation 40 (9.57) 20 (8.58) 20 (10.81)
Medium risk occupation 172 (41.15) 98 (42.06) 74 (40.00)
High-risk occupation 206 (49.28) 115 (49.36) 91 (49.19)
Vaccine 0.180 0.670
Unvaccinated 27 (6.46) 14 (6.01) 13 (7.03)
Vaccinated 391 (93.54) 219 (93.99) 172 (92.97)
Previous history 1.820 0.177
Yes 70 (16.79) 34 (14.59) 36 (19.57)
No 347 (83.21) 199 (85.41) 148 (80.43)
Treatment before admission 2.423 0.120
No 368 (88.04) 200 (85.84) 168 (90.81)
Yes 50 (11.96) 33 (14.16) 17 (9.19)
Group B 509 427 82
Age 39 [28, 52] 34 [28, 48] −1.035 0.301
Sex
Male 296 (58.15) 249 (58.31) 47 (57.32) 0.028 0.867
Female 213 (41.85) 178 (41.69) 35 (42.68)
Occupation 6.012 0.049*
Low-risk occupation 45 (8.84) 32 (7.49) 13 (15.85)
Medium risk occupation 270 (53.05) 229 (53.63) 41 (50.00)
High-risk occupation 194 (38.11) 166 (38.88) 28 (34.15)
Vaccine
Unvaccinated 36 (7.11) 31 (7.31) 5 (6.10) 0.153 0.696
Vaccinated 470 (92.89) 393 (92.69) 77 (93.90)
Previous history 0.020 0.888
Yes 60 (11.88) 50 (11.79) 10 (12.35)
No 445 (88.12) 374 (88.21) 71 (87.65)
Treatment before admission 0.621 0.431
No 459 (90.18) 387 (90.63) 72 (87.80)
Yes 50 (9.82) 40 (9.37) 10 (12.20)

*p < 0.05, the difference is statistically significant.

3.5. Clinical data and laboratory examinations

In Group A, there was a statistically significant difference in red blood cell count (z = −2.800, p = 0.005). However, there were no statistically significant differences between the two groups in terms of TCM symptoms at admission, fever after admission, comprehensive evaluation of medical records, TCM diagnosis at discharge, and various indicators (temperature, breath, heart rate, systolic blood pressure, diastolic blood pressure, oxygen saturation, total bilirubin, direct bilirubin, creatinine, white blood cell count, bacterial count, hemoglobin, platelet count, albumin, glutamic-pyruvic transaminase, glutamic oxaloacetic transaminase, blood urea nitrogen, NLR) (p > 0.05). In Group B, there were statistically significant differences in direct bilirubin (z = −2.605, p = 0.009) and platelet count (z = −2.988, p = 0.003). However, there were no statistically significant differences between the two groups in terms of TCM symptoms at admission, fever after admission, comprehensive evaluation of medical records, TCM diagnosis at discharge, and various indicators (temperature, breath, heart rate, systolic blood pressure, diastolic blood pressure, oxygen saturation, total bilirubin, red blood cell count, creatinine, white blood cell count, bacterial count, hemoglobin, albumin, glutamic-pyruvic transaminase, glutamic oxaloacetic transaminase, blood urea nitrogen, NLR) (p > 0.05) (Tables 6, 7).

Table 6.

Comparison of clinical data of patients with different length of stay after admission [P25, P75].

Hospital stay duration Clinical data Total Category χ2/z p
Stable nucleic acid CT values (660) Fluctuating nucleic acid CT values (267)
Group A 418 233 185
TCM symptom 0.600 0.438
No 68 (16.27) 35 (15.02) 33 (17.84)
Yes 350 (83.73) 198 (84.98) 152 (82.16)
Fever after admission 1.188 0.276
Yes 111 (62.01) 61 (58.65) 50 (66.67)
No 68 (37.99) 43 (41.35) 25 (33.33)
Comprehensive evaluation of admission records 2.380 0.123
Light 350 (98.04) 202 (99.02) 148 (96.73)
Ordinary 7 (1.96) 2 (0.98) 5 (3.27)
Discharged TCM diagnosis 3.429 0.180
Lung meridian stagnation fire syndrome 215 (51.44) 113 (48.50) 102 (55.14)
Evidence of cold and dampness invading outside 189 (45.22) 114 (48.93) 75 (40.54)
Others 14 (3.35) 6 (2.58) 8 (4.32)
Group B 509 427 82
TCM symptom 0.283 0.595
No 65 (12.77) 56 (13.11) 9 (10.98)
Yes 444 (87.23) 371 (86.89) 73 (89.02)
Fever after admission 0.561 0.454
Yes 81 (54.36) 68 (53.13) 13 (61.90)
No 68 (45.64) 60 (46.88) 8 (38.10)
Comprehensive evaluation of admission records 0.022 0.883
Light 440 (98.43) 368 (98.40) 72 (98.63)
Ordinary 7 (1.57) 6 (1.60) 1 (1.37)
Discharged TCM diagnosis 1.045 0.593
Lung meridian stagnation fire syndrome 305 (59.92) 252 (59.02) 53 (64.63)
Evidence of cold and dampness invading outside 186 (36.54) 159 (37.24) 27 (32.93)
Others 18 (3.54) 16 (3.75) 2 (2.44)

*p < 0.05, the difference is statistically significant.

Table 7.

Comparison of laboratory indicators of patients with different length of stay [P25, P75].

Hospital stay duration Various indicators Category z p
Stable nucleic acid CT values (660) Fluctuating nucleic acid CT values (267)
Group A 233 185
Temperature 36 [36, 37] 36 [36, 37] −0.483 0.629
Breath 18 [18, 20] 18 [18, 20] −0.456 0.648
Heart rate 90 [80, 101.5] 88 [80, 100] −1.812 0.070
Systolic blood pressure 122 [120, 130] 120 [120, 130] −1.281 0.200
Diastolic blood pressure 80 [75, 84] 80 [71, 82] −0.561 0.575
Blood oxygen saturation 98 [96, 99] 98 [96, 99] −0.184 0.854
Total bilirubin 11 [8, 14] 10 [7, 14] −0.964 0.335
Direct bilirubin 3 [2, 4] 3 [2, 4] −0.892 0.372
Creatinine 67 [53, 78] 68 [51, 79] −0.083 0.934
Red blood cell count 6 [2, 15] 4 [2, 12] −2.800 0.005*
White blood cell count 8 [4, 21.5] 7 [4, 16] −0.900 0.368
Bacterial count 21 [4, 164] 12 [4, 135.5] −0.920 0.358
Hemoglobin 144 [130, 158] 146 [131, 157.5] −0.420 0.674
Platelet count 195 [166.5, 237.5] 191 [159.5, 237] −0.984 0.325
Albumin 43 [40, 45] 42 [39, 45] −1.037 0.300
Glutamic-pyruvic transaminase 20 [11, 34] 22 [12, 38] −0.928 0.353
Glutamic oxaloacetic transaminase 21 [16, 28] 22 [16.5, 29.5] −0.769 0.442
Urea nitrogen 4 [3, 5] 4 [3, 5] −0.479 0.632
NLR (Neutral Particle Count/Lymphocyte Count) 1.38 [0.975, 2.225] 1.35 [0.89, 2.0] −1.131 0.258
Group B 427 82
Temperature 36 [36, 37] 36 [36, 37] −0.508 0.611
Breath 18 [18, 20] 18.5 [18, 20] −0.117 0.907
Heart rate 90 [80, 100] 86 [78, 98] −1.778 0.075
Systolic blood pressure 120 [118, 128] 120 [116, 127.5] −0.323 0.746
Diastolic blood pressure 80 [72, 82] 79 [70, 81.25] −0.789 0.430
Blood oxygen saturation 98 [97, 99] 98 [97, 99] −0.589 0.556
Total bilirubin 10 [0, 14] 10 [8, 14] −1.417 0.157
Direct bilirubin 3 [0, 4] 3 [2, 4] −2.605 0.009*
Creatinine 58 [0, 73] 61.5 [47.75, 76] −1.735 0.083
Red blood cell count 4 [2, 13] 6 [1, 13] −1.035 0.301
White blood cell count 7 [4, 22] 7 [4, 17] −0.575 0.565
Bacterial count 22 [5, 150] 20 [4, 170.25] −0.123 0.902
Hemoglobin 144 [132, 158] 141 [126.5, 157] −1.442 0.149
Platelet count 213 [172, 255] 186.5 [157.5, 226.25] −2.988 0.003*
Albumin 42 [0, 44] 42 [39, 44.25] −1.665 0.096
Glutamic-pyruvic transaminase 17 [0, 32] 18.5 [12, 31.25] −1.036 0.300
Glutamic oxaloacetic transaminase 19 [0, 25] 20 [15, 26.25] −1.291 0.197
Urea nitrogen 4 [0, 5] 4 [3, 5] −1.026 0.305
NLR (Neutral Particle Count/Lymphocyte Count) 1.34 [0.93, 1.82] 1.3262 ± 0.90650 −1.243 0.214

*p < 0.05, the difference is statistically significant.

3.6. Logistic regression analysis of factors influencing nucleic acid CT value fluctuations in Group B

Factors that showed statistically significant differences in the univariate analysis of Group B, including occupational composition, direct bilirubin, and platelet count, were included in a binary logistic regression model. Nucleic acid CT value fluctuation was the dependent variable, and the three aforementioned variables, along with age as a forced variable, were entered into the model using a forward: LR method. The results showed that occupational composition (high-risk occupation, p = 0.005, OR = 3.159) and direct bilirubin (p = 0.029, OR = 0.997) were significantly associated with nucleic acid CT value fluctuations. None of the other indicators were independent risk factors for nucleic acid CT value fluctuations (p > 0.05) (Table 8).

Table 8.

Logistic regression analysis of fluctuations in nucleic acid CT values of patients in group B.

Risk factors OR (95%CI) p
Age 0.344 (0.971–1.003) 0.050
Occupation
Low-risk occupation 0.015
Medium risk occupation 1.103 (0.645–1.889) 0.720
High-risk occupation 3.159 (1.418–7.035) 0.005*
Direct bilirubin 0.997 (0.994–1.000) 0.029*

*p < 0.05, the difference is statistically significant.

4. Discussion

Since the onset of the COVID-19 pandemic in 2019, more than 5 years have elapsed. During this period, the virus has evolved numerous variants, posing a significant public health challenge globally. Patients who test negative for nucleic acid may still be affected by COVID-19 (40). Among the variant strains, the Omicron variant has shown a decrease in pathogenicity but possesses strong infectivity and rapid transmission, causing significant impact in certain regions (41, 42). The fluctuation in nucleic acid CT values has undoubtedly posed challenges to the normalization of epidemic prevention and control, severely affecting people’s normal lives and mental well-being (43). Studies have found that approximately one-fourth of patients experience fluctuations in nucleic acid CT values (44), which may persist or recur over a prolonged period (45). Significant correlations have been observed between nucleic acid CT values and factors such as length of hospital stay, vaccination status (46), age (47), and albumin levels (48).

In this study, there was a statistically significant difference in the occupational composition between the group with nucleic acid CT value fluctuations and the group without fluctuations (χ2 = 7.043, p = 0.03). It was found that the viral shedding time of healthcare workers was prolonged (49), and the probability of nucleic acid CT value fluctuations increased with the nature of their occupation (39). The likelihood of contracting COVID-19 is inevitably associated with the workplace and occupation (50, 51). Univariate analysis of nucleic acid CT value fluctuations revealed a significant correlation with hospitalization duration (z = −12.672, p = 0.000), consistent with previous research that showed a correlation between nucleic acid CT value fluctuations and hospitalization duration (p = 0.00018, 13). Therefore, nucleic acid CT fluctuations are an important factor related to length of stay (38, 52). This suggests a significant correlation between nucleic acid CT value fluctuations and hospitalization duration, and binary logistic regression analysis results indicate a positive correlation between nucleic acid CT value fluctuations and hospital stay duration, indicating that the longer the hospitalization duration, the greater the risk of nucleic acid CT value fluctuations. Some studies have indicated that older adult patients, due to their weaker immune system and higher prevalence of underlying diseases such as hypertension and diabetes, have a lower clearance rate and tolerance to the virus, making them more prone to nucleic acid CT value fluctuations (53, 54). However, the results of this study showed no significant correlation between nucleic acid CT value fluctuations and age or medical history, which is inconsistent with other related studies (39, 48, 55). Given the weakened immune response and decreased organ reserve capacity in the older adult, leukocyte count and C-reactive protein levels are associated with nucleic acid CT values (56). Therefore, it is crucial to pay attention to this population to prevent the occurrence of nucleic acid CT value fluctuations, which can cause irreversible damage to the body, aligning with the research on nucleic acid CT value fluctuations in the Northeast region (57). This suggests that the influence of gender composition on nucleic acid CT value fluctuations may be region-specific, while age may be related to the fact that the subjects in this study were predominantly young and middle-aged individuals.

Although this study found no statistically significant difference between the fluctuation of patient nucleic acid CT values and vaccination history, COVID-19 vaccines have shown high efficacy and good tolerability against the original strain and related variants. Both two-dose and three-dose regimens provide good protection against Omicron, although efficacy may decrease over time and compared to other strains (58–60). This research does not establish a significant correlation between the fluctuations in the nucleic acid CT values and vaccination. However, it still emphasizes the effectiveness of COVID-19 vaccination in preventing and controlling the Omicron variant, and encourages people to get vaccinated to prevent reinfection. Nucleic acid CT values have certain relationships with factors such as NLR, white blood cell count, C-reactive protein, and platelet count (56, 61–63). This study shows significant correlations between nucleic acid CT fluctuation and patient creatinine, platelet count, alanine aminotransferase, and aspartate aminotransferase, but no significant correlation with white blood cell count, NLR (neutrophil count/lymphocyte count), or hemoglobin. This suggests that the strength of a patient’s immune system and the normal function of the liver are related to nucleic acid CT fluctuation. Binary logistic regression analysis reveals that platelet count (p = 0.019, OR = 0.996) is an independent factor influencing nucleic acid CT value fluctuation and is negatively correlated, which is consistent with previous studies. This indicates that the stronger the patient’s immune system, the lower the risk of the fluctuation of nucleic acid CT values fluctuation. Studies have found a high risk of arrhythmias in COVID-19 patients (64). The reasons for arrhythmias in COVID-19 are still unclear and may be a direct effect of the virus or adverse reactions to medications used for treatment. This is consistent with the statistically significant difference in nucleic acid CT fluctuation and heart rate (z = −2.224, p = 0.026) observed in this study. Binary logistic regression analysis shows that heart rate (p = 0.036, OR = 0.979) is an independent factor influencing nucleic acid CT value fluctuation and is negatively correlated. This suggests that paying attention to cardiovascular health and receiving anti-arrhythmia treatment has a significant effect on preventing nucleic acid CT fluctuation. Further research has found that regular aerobic exercise and its effect on heart rate are consistent with the median heart rate results in both groups (65). This indicates that regular aerobic exercise, which increases myocardial oxygen consumption and enhances immune function, is an effective approach to control nucleic acid CT fluctuation.

The study found that red blood cell count is an influencing factor for nucleic acid CT fluctuation in Group A, which is consistent with the well-established manifestation of anemia in COVID-19 infection (66–68). Although anemia does not directly affect the mortality rate of COVID-19 patients, its impact on the older adult should not be overlooked. Due to their diminished immunity and general frailty, older adult individuals are less likely to recover quickly from COVID-19, leading to prolonged hospital stays and severely diminishing their quality of life. In Group B, occupational composition, direct bilirubin, and platelet count are influencing factors for nucleic acid CT fluctuation, and binary logistic regression analysis shows that occupational composition and direct bilirubin are independent factors influencing nucleic acid CT value fluctuation and are positively and negatively correlated, respectively. This indicates that short-term hospitalized patients in high-risk occupations are more prone to nucleic acid CT fluctuation, which is consistent with the factors influencing nucleic acid CT fluctuation mentioned earlier and further emphasizes the higher risk of nucleic acid CT fluctuation in short-term hospitalized patients engaged in high-risk occupations. For short-term hospitalized patients, the lower the direct bilirubin within the normal range, the higher the risk of nucleic acid CT fluctuation, which is consistent with research showing that direct bilirubin prolongs viral shedding time in Omicron patients (69).

5. Conclusion

Based on the retrospective study, it was found that the occupation composition, hospital stay duration, heart rate, creatinine, platelet count, alanine transaminase, and aspartate transaminase were factors influencing the fluctuation of nucleic acid CT values in COVID-19 patients. Among them, hospital stay duration, platelet count, and heart rate were identified as independent factors affecting the fluctuation of nucleic acid CT values, with a positive correlation observed with the hospital stay duration and a negative correlation with platelet count and heart rate. Analyzing the relationship between hospital stay duration and the fluctuation of nucleic acid CT values, it was determined that red blood cell count was a factor influencing the fluctuation of nucleic acid CT values fluctuation in Group A patients, while occupation composition, direct bilirubin, and platelet count were factors influencing the fluctuation of nucleic acid CT values fluctuation in Group B patients. In Group B, occupation composition and direct bilirubin were identified as independent factors affecting the fluctuation of nucleic acid CT values, positively correlated with occupational risk and negatively correlated with direct bilirubin.

Therefore, enhancing patients’ immune function, increasing physical exercise to improve myocardial oxygen consumption, reducing hospital stay duration, and closely monitoring liver function to prevent liver function abnormalities at the initial stage of hospitalization are effective measures for controlling the fluctuation of nucleic acid CT values in COVID-19 patients. However, due to the limited clinical data collected, these findings may not comprehensively and accurately reflect the factors influencing the fluctuation of nucleic acid CT values in COVID-19. Additionally, the regional limitations of the data collection may not represent all regions. Therefore, future research should adopt large sample sizes and a multicenter approach to provide reliable evidence for comprehensive and accurate prediction of nucleic acid CT value fluctuation in COVID-19, thus supporting data-driven strategies for epidemic prevention and control in the post-pandemic era.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by the Ethics Committee of the Affiliated Hospital of Changchun University of Traditional Chinese Medicine (Approval No: CCZYFYLL2022 Approval Letter-020; CCZYFYLL2022 Approval Letter-021). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

ZC: Writing – original draft. FS: Data curation, Writing – original draft. HD: Data curation, Writing – original draft. ZT: Data curation, Writing – original draft. YC: Conceptualization, Data curation, Writing – review & editing. WY: Data curation, Writing – review & editing. SH: Writing – review & editing, Conceptualization, Funding acquisition. LS: Conceptualization, Writing – review & editing, Funding acquisition.

Funding Statement

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the following projects: A randomized, open, positive control drug, fibrate test clinical study of Jiejixuanfeichuyi granules against COVID-19 (Omicron variant) infection (2022ZYLCYJ04-1); A cross-sectional study of post-coronavirus disease 2019 syndrome in Jilin province and a clinical study of TCM efficacy evaluation (20230203189SF); A retrospective study of the prevention and treatment of COVID-19 in Changchun University of Traditional Chinese Medicine (2022219). We gratefully acknowledge the funding of the above projects. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2024.1377135/full#supplementary-material

Table_1.XLSX (56.7KB, XLSX)

References

  • 1.Chilamakuri R, Agarwal S. COVID-19: characteristics and therapeutics. Cells. (2021) 10:206. doi: 10.3390/cells10020206, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Muhammad Waqar M, Javaria M, Saira S, Masooma Batool S, Hira A. Severe acute respiratory syndrome (Saras Covid-2): a comprehensive review. Quantum J Med Health Sci. (2021) 1:25–33. [Google Scholar]
  • 3.Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. (2022) 7:141. doi: 10.1038/s41392-022-00997-x, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Powell AA, Kirsebom F, Stowe J, Ramsay ME, Lopez-Bernal J, Andrews N, et al. Protection against symptomatic infection with delta (B.1.617.2) and Omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Lancet Infect Dis. (2023) 23:435–44. doi: 10.1016/S1473-3099(22)00729-0, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. (2022) 603:700–5. doi: 10.1038/s41586-022-04462-1, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Shuai H, Chan JF, Hu B, Chai Y, Yuen TT, Yin F, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. (2022) 603:693–9. doi: 10.1038/s41586-022-04442-5, PMID: [DOI] [PubMed] [Google Scholar]
  • 7.Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. (2022) 603:687–92. doi: 10.1038/s41586-022-04441-6, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chekol Abebe E, Tiruneh GMM, Behaile TMA, Asmamaw Dejenie T, Mengie Ayele T, Tadele Admasu F, et al. Mutational pattern, impacts and potential preventive strategies of Omicron SARS-CoV-2 variant infection. Infect Drug Resist. (2022) 15:1871–87. doi: 10.2147/IDR.S360103, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. PLoS Med. (2022) 19:e1003987. doi: 10.1371/journal.pmed.1003987, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hansen CH, Friis NU, Bager P, Stegger M, Fonager J, Fomsgaard A, et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 Omicron subvariant: a nation-wide population-based study in Denmark. Lancet Infect Dis. (2023) 23:167–76. doi: 10.1016/S1473-3099(22)00595-3, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zhu KL, Jiang XL, Zhan BD, Wang XJ, Xia X, Cao GP, et al. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. Cell Rep. (2023) 42:112075. doi: 10.1016/j.celrep.2023.112075, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to may 2020. Euro Surveill. (2020) 25:2001483. doi: 10.2807/1560-7917.ES.2020.25.32.2001483, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lu J, Peng J, Xiong Q, Liu Z, Lin H, Tan X, et al. Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. EBioMedicine. (2020) 59:102960. doi: 10.1016/j.ebiom.2020.102960, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, et al. Duration of infectious virus shedding by SARS-CoV-2 Omicron variant-infected vaccinees. Emerg Infect Dis. (2022) 28:998–1001. doi: 10.3201/eid2805.220197, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Qureshi A, Syed Sulaiman SA, Kumar N, Qureshi P. Knowledge, perception, and fear among the global population towards newly evoked variant Omicron (B.1.1.529). PLoS One. (2022) 17:e0270761. doi: 10.1371/journal.pone.0270761, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. (2022) 9:815–27. doi: 10.1016/S2215-0366(22)00260-7, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Rogers JP, Lewis G. Neuropsychiatric sequelae of COVID-19: long-lasting, but not uniform. Lancet Psychiatry. (2022) 9:762–3. doi: 10.1016/S2215-0366(22)00302-9, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wang H, Sun K, Wang Y. Exploring the Chinese Public's perception of Omicron variants on social media: LDA-based topic modeling and sentiment analysis. Int J Environ Res Public Health. (2022) 19:8377. doi: 10.3390/ijerph19148377, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. (2020) 9:573–86. doi: 10.1007/s40121-020-00324-3, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rajyalakshmi B, Samavedam S, Reddy PR, Aluru N. Prognostic value of "cycle threshold" in confirmed COVID-19 patients. Indian J Crit Care Med. (2021) 25:322–6. doi: 10.5005/jp-journals-10071-23765, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Sikhosana ML, Welch R, Musekiwa A, Makatini Z, Ebonwu J, Blumberg L, et al. Association between SARS-CoV-2 gene specific Ct values and COVID-19 associated in-hospital mortality. Front Epidemiol. (2024) 4:1375975. doi: 10.3389/fepid.2024.1375975, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Shoaib N, Noureen N, Faisal A, Zaheer M, Imran M, Ahsan A, et al. Factors associated with cycle threshold values (Ct-values) of SARS-CoV2-rRT-PCR. Mol Biol Rep. (2022) 49:4101–6. doi: 10.1007/s11033-022-07360-x, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Penney J, Jung A, Koethe B, Doron S. Cycle threshold values and SARS-CoV-2: relationship to demographic characteristics and disease severity. J Med Virol. (2022) 94:3978–81. doi: 10.1002/jmv.27752, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Acer O, Genc Bahce Y, Ozudogru O. Association of viral load with age, gender, disease severity, and death in severe acute respiratory syndrome coronavirus 2 variants. J Med Virol. (2022) 94:3063–9. doi: 10.1002/jmv.27677, PMID: [DOI] [PubMed] [Google Scholar]
  • 25.Ur Rehman M, Sajjad Naqvi S, Ullah R, Arshad N, Ammad M, Ul Ain Q, et al. Elucidation of correlation between SARS-CoV-2 RdRp and N gene cycle threshold (Ct) by RT-PCR with age and gender. Clin Chim Acta. (2022) 533:42–7. doi: 10.1016/j.cca.2022.06.008, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Trunfio M, Richiardi L, Alladio F, Staffilano E, Longo B, Venuti F, et al. Determinants of SARS-CoV-2 contagiousness in household contacts of symptomatic adult index cases. Front Microbiol. (2022) 13:829393. doi: 10.3389/fmicb.2022.829393, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Karahasan Yagci A, Sarinoglu RC, Bilgin H, Yanilmaz O, Sayin E, Deniz G, et al. Relationship of the cycle threshold values of SARS-CoV-2 polymerase chain reaction and total severity score of computerized tomography in patients with COVID 19. Int J Infect Dis. (2020) 101:160–6. doi: 10.1016/j.ijid.2020.09.1449, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.El Zein S, Chehab O, Kanj A, Akrawe S, Alkassis S, Mishra T, et al. SARS-CoV-2 infection: initial viral load (iVL) predicts severity of illness/outcome, and declining trend of iVL in hospitalized patients corresponds with slowing of the pandemic. PLoS One. (2021) 16:e0255981. doi: 10.1371/journal.pone.0255981, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kawasuji H, Morinaga Y, Tani H, Yoshida Y, Takegoshi Y, Kaneda M, et al. SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19. J Med Virol. (2022) 94:147–53. doi: 10.1002/jmv.27282, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Maltezou HC, Raftopoulos V, Vorou R, Papadima K, Mellou K, Spanakis N, et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis. (2021) 223:1132–8. doi: 10.1093/infdis/jiaa804, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Tom MR, Mina MJ. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clin Infect Dis. (2020) 71:2252–4. doi: 10.1093/cid/ciaa619, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Salvatore PP, Dawson P, Wadhwa A, Rabold EM, Buono S, Dietrich EA, et al. Epidemiological correlates of polymerase chain reaction cycle threshold values in the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2021) 72:e761–7. doi: 10.1093/cid/ciaa1469, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zhuang X, Zheng Y, Wei S, Zhai W, Song Q, Chen M, et al. Can the nucleic acid Ct value of discharged patients infected with SARS-CoV-2 Omicron variant be 35?--a retrospective study on fluctuation of nucleic acid Ct values in SNIEC mobile cabin hospital. Front Cell Infect Microbiol. (2022) 12:1059880. doi: 10.3389/fcimb.2022.1059880, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wang X, Fan Q, Li Y, Xiao J, Huang Y, Guo T, et al. The changes in psychological symptoms of COVID-19 patients after "re-positive". Front Psych. (2022) 13:1010004. doi: 10.3389/fpsyt.2022.1010004, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Wang J, Zhang SX, Na JR, Zhang LL, Zhang YH, Chu JJ, et al. A comparative study of virus nucleic acid re-positive and non-re-positive patients infected with SARS-CoV-2 Delta variant strain in the Ningxia Hui Autonomous Region. Front Public Health. (2022) 10:1023797. doi: 10.3389/fpubh.2022.1023797, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Bustos P, Tambley C, Acevedo A, Andrade W, Leal G, Vidal D, et al. Quantitative detection of SARS-CoV-2 RNA in nasopharyngeal samples from infected patients with mild disease. J Med Virol. (2021) 93:2439–45. doi: 10.1002/jmv.26761, PMID: [DOI] [PubMed] [Google Scholar]
  • 37.National Health Commission of the People’s Republic of China (2022). Guideline of diagnosis and treatment of novel coronavirus pneumonia (the 9th version) [EB/OL].
  • 38.Hu C, Liu YK, Sun QD, Du Z, Fang YQ, Guo F, et al. Clinical characteristics and risk factors for a prolonged length of stay of patients with asymptomatic and mild COVID-19 during the wave of Omicron from Shanghai, China. BMC Infect Dis. (2022) 22:947. doi: 10.1186/s12879-022-07935-w, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Li R, Jin C, Zhang L, Kong D, Hu K, Xuan M, et al. Clinical characteristics and risk factors analysis of viral shedding time in mildly symptomatic and asymptomatic patients with SARS-CoV-2 Omicron variant infection in Shanghai. Front Public Health. (2022) 10:1073387. doi: 10.3389/fpubh.2022.1073387, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Mazhar MW, Raza A, Shaheen T, Zubair M, Mahmood J, Tahir H, et al. Detection of SARS-CoV-2 by using real-time PCR nasopharyngeal swabs in suspected patients and their clinical medication. Sens Int. (2022) 3:100148. doi: 10.1016/j.sintl.2021.100148, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Team CC-R. SARS-CoV-2 B.1.1.529 (Omicron) variant – United States, December 1-8, 2021. MMWR Morb Mortal Wkly Rep. (2021) 70:1731–4. doi: 10.15585/mmwr.mm7050e1, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Hirabara SM, Serdan TDA, Gorjao R, Masi LN, Pithon-Curi TC, Covas DT, et al. SARS-COV-2 variants: differences and potential of immune evasion. Front Cell Infect Microbiol. (2021) 11:781429. doi: 10.3389/fcimb.2021.781429, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Nainu F, Abidin RS, Bahar MA, Frediansyah A, Emran TB, Rabaan AA, et al. SARS-CoV-2 reinfection and implications for vaccine development. Hum Vaccin Immunother. (2020) 16:3061–73. doi: 10.1080/21645515.2020.1830683, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Yang Y, You Y, Liu Y, Geng L, Huang L, Zhou H, et al. Factors associated with negative conversion of viral RNA in hospitalized children infected with SARS-CoV-2 Omicron variant in Shanghai, China: a retrospective analysis. BMC Infect Dis. (2023) 23:264. doi: 10.1186/s12879-023-08223-x, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Li Y, Guo D, Zhang B, Wu W, Cai Y, Zhang X. Tracking analysis of viral nucleic acid Ct value in patients with re-positive SARS-CoV-2 infection. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. (2023) 35:427–30. doi: 10.3760/cma.j.cn121430-20230107-01130, PMID: [DOI] [PubMed] [Google Scholar]
  • 46.Zhang W, Zhou S, Wang G, Cao M, Sun D, Lu W, et al. Clinical predictors and RT-PCR profile of prolonged viral shedding in patients with SARS-CoV-2 Omicron variant in Shanghai: a retrospective observational study. Front Public Health. (2022) 10:1015811. doi: 10.3389/fpubh.2022.1015811, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Hu X, Xing Y, Jia J, Ni W, Liang J, Zhao D, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Sci Total Environ. (2020) 728:138812. doi: 10.1016/j.scitotenv.2020.138812, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Cogliati Dezza F, Oliva A, Cancelli F, Savelloni G, Valeri S, Mauro V, et al. Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. Diagn Microbiol Infect Dis. (2021) 100:115347. doi: 10.1016/j.diagmicrobio.2021.115347, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Keske S, Guney-Esken G, Vatansever C, Besli Y, Kuloglu ZE, Nergiz Z, et al. Duration of infectious shedding of SARS-CoV-2 Omicron variant and its relation with symptoms. Clin Microbiol Infect. (2023) 29:221–4. doi: 10.1016/j.cmi.2022.07.009, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Gomez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Diaz ZM, Wyssmann BM, et al. COVID-19 in health-care workers: a living systematic review and Meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol. (2021) 190:161–75. doi: 10.1093/aje/kwaa191, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Gholami M, Fawad I, Shadan S, Rowaiee R, Ghanem H, Hassan Khamis A, et al. COVID-19 and healthcare workers: a systematic review and meta-analysis. Int J Infect Dis. (2021) 104:335–46. doi: 10.1016/j.ijid.2021.01.013, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Yin C, Hu B, Li K, Liu X, Wang S, He R, et al. Clinical characteristics and prognostic nomograms of 12555 non-severe COVID-19 cases with Omicron infection in Shanghai. BMC Infect Dis. (2023) 23:606. doi: 10.1186/s12879-023-08582-5, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Ren X, Ren X, Lou J, Wang Y, Huang Q, Shi Y, et al. A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR. EClinicalMedicine. (2021) 34:100839. doi: 10.1016/j.eclinm.2021.100839, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Kang W, Yang P, Dang B, Zhang W, Gang Y, Wang W, et al. Dynamics of disease characteristics and viral RNA decay in patients with asymptomatic and mild infections during the Omicron wave in Shanghai, China: a retrospective cohort study. Int J Infect Dis. (2023) 130:60–70. doi: 10.1016/j.ijid.2023.02.020, PMID: [DOI] [PubMed] [Google Scholar]
  • 55.Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. (2022) 5:e2238804. doi: 10.1001/jamanetworkopen.2022.38804, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Wang M, Mi H, Li N, Shi Q, Sun W, He T, et al. Association between the overall burden of comorbidity and Ct values among the older patients with Omicron infection: mediated by inflammation. Front Immunol. (2023) 14:1145044. doi: 10.3389/fimmu.2023.1145044, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Li H, Zhu M, Zhang P, Yan X, Niu J, Wang Z, et al. Milder symptoms and shorter course in patients with re-positive COVID-19: a cohort of 180 patients from Northeast China. Front Microbiol. (2022) 13:989879. doi: 10.3389/fmicb.2022.989879, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. (2022) 28:202–21. doi: 10.1016/j.cmi.2021.10.005, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of bivalent boosters against severe Omicron infection. N Engl J Med. (2023) 388:764–6. doi: 10.1056/NEJMc2215471, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. (2022) 327:639–51. doi: 10.1001/jama.2022.0470, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Salman E, Celikbilek N, Aydogan S, Ozdem B, Gokay S, Kirca F, et al. Investigation of the relationship of systemic immune-inflammation index, C-reactive protein and Interleukin-6 with viral dynamics in patients with COVID-19. Mikrobiyol Bul. (2021) 55:539–52. doi: 10.5578/mb.20219706, PMID: [DOI] [PubMed] [Google Scholar]
  • 62.Stegeman I, Ochodo EA, Guleid F, Holtman GA, Yang B, Davenport C, et al. Routine laboratory testing to determine if a patient has COVID-19. Cochrane Database Syst Rev. (2020) 11:CD013787. doi: 10.1002/14651858.CD013787, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res. (2020) 21:74. doi: 10.1186/s12931-020-01338-8, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Manolis AS, Manolis AA, Manolis TA, Apostolopoulos EJ, Papatheou D, Melita H. COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med. (2020) 30:451–60. doi: 10.1016/j.tcm.2020.08.002, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Alawna M, Amro M, Mohamed AA. Aerobic exercises recommendations and specifications for patients with COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. (2020) 24:13049–55. doi: 10.26355/eurrev_202012_24211, PMID: [DOI] [PubMed] [Google Scholar]
  • 66.Bergamaschi G, Borrelli de Andreis F, Aronico N, Lenti MV, Barteselli C, Merli S, et al. Anemia in patients with COVID-19: pathogenesis and clinical significance. Clin Exp Med. (2021) 21:239–46. doi: 10.1007/s10238-020-00679-4, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. (2020) 35:763–73. doi: 10.1007/s10654-020-00678-5, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Yuan X, Huang W, Ye B, Chen C, Huang R, Wu F, et al. Changes of hematological and immunological parameters in COVID-19 patients. Int J Hematol. (2020) 112:553–9. doi: 10.1007/s12185-020-02930-w, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Zhang L, Xie S, Lyu F, Liu C, Li C, Liu W, et al. Predictive value of immunoglobulin G, activated partial thromboplastin time, platelet, and indirect bilirubin for delayed viral clearance in patients infected with the Omicron variant. PeerJ. (2023) 11:e15443. doi: 10.7717/peerj.15443, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table_1.XLSX (56.7KB, XLSX)

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.


Articles from Frontiers in Public Health are provided here courtesy of Frontiers Media SA

RESOURCES